Literature DB >> 20154580

Examining the promise of HIV elimination by 'test and treat' in hyperendemic settings.

Peter J Dodd1, Geoff P Garnett, Timothy B Hallett.   

Abstract

BACKGROUND: It has been suggested that a new strategy for HIV prevention, 'Universal Test and Treat', whereby everyone is tested for HIV once a year and treated immediately with antiretroviral therapy (ART) if they are infected, could 'eliminate' the epidemic and reduce ART costs in the long term.
METHODS: We investigated the impact of test-and-treat interventions under a variety of assumptions about the epidemic using a deterministic mathematical model.
RESULTS: Our model shows that such an intervention can substantially reduce HIV transmission, but that impact depends crucially on the epidemiological context; in some situations, less aggressive interventions achieve the same results, whereas in others, the proposed intervention reduces HIV by much less. It follows that testing every year and treating immediately is not necessarily the most cost-efficient strategy. We also show that a test-and-treat intervention that does not reach full implementation or coverage could, perversely, increase long-term ART costs.
CONCLUSION: Interventions that prevent new infections through ART scale-up may hold substantial promise. However, as plans move forward, careful consideration should be given to the nature of the epidemic and the potential for perverse outcomes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20154580      PMCID: PMC2852517          DOI: 10.1097/QAD.0b013e32833433fe

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  46 in total

Review 1.  The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic.

Authors:  Julio S G Montaner; Robert Hogg; Evan Wood; Thomas Kerr; Mark Tyndall; Adrian R Levy; P Richard Harrigan
Journal:  Lancet       Date:  2006-08-05       Impact factor: 79.321

2.  Data are lacking for quantifying HIV transmission risk in the presence of effective antiretroviral therapy.

Authors:  David P Wilson
Journal:  AIDS       Date:  2009-07-17       Impact factor: 4.177

3.  Universal voluntary HIV testing and immediate antiretroviral therapy.

Authors:  Allison Ruark; James D Shelton; Daniel T Halperin; Maria J Wawer; Ronald H Gray
Journal:  Lancet       Date:  2009-03-28       Impact factor: 79.321

4.  Universal voluntary HIV testing and immediate antiretroviral therapy.

Authors:  Ralf Jürgens; Jonathan Cohen; Daniel Tarantola; Mark Heywood; Robert Carr
Journal:  Lancet       Date:  2009-03-28       Impact factor: 79.321

5.  Universal voluntary HIV testing and immediate antiretroviral therapy.

Authors:  Ying-Hen Hsieh; Hector de Arazoza
Journal:  Lancet       Date:  2009-03-28       Impact factor: 79.321

6.  The role of testing and counselling for HIV prevention and care in the era of scaling-up antiretroviral therapy.

Authors:  T B Hallett; S Dube; I Cremin; B Lopman; A Mahomva; G Ncube; O Mugurungi; S Gregson; G P Garnett
Journal:  Epidemics       Date:  2009-03-17       Impact factor: 4.396

7.  Strategies for limiting the spread of HIV in developing countries: conclusions based on studies of the transmission dynamics of the virus.

Authors:  G P Garnett; R M Anderson
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1995-08-15

8.  No difference in clinical progression between patients infected with the predominant human immunodeficiency virus type 1 circulating recombinant form (CRF) 02_AG strain and patients not infected with CRF02_AG, in Western and West-Central Africa: a four-year prospective multicenter study.

Authors:  Christian Laurent; Anke Bourgeois; Mame Awa Faye; Rose Mougnutou; Moussa Seydi; Mandoumbé Gueye; Florian Liégeois; Coumba Touré Kane; Christelle Butel; Josephine Mbuagbaw; Léopold Zekeng; Souleymane Mboup; Eitel Mpoudi-Ngolé; Martine Peeters; Eric Delaporte
Journal:  J Infect Dis       Date:  2002-07-19       Impact factor: 5.226

9.  HIV incidence during a cluster-randomized trial of two strategies providing voluntary counselling and testing at the workplace, Zimbabwe.

Authors:  Elizabeth L Corbett; Beauty Makamure; Yin Bun Cheung; Ethel Dauya; Ronnie Matambo; Tsitsi Bandason; Shungu S Munyati; Peter R Mason; Anthony E Butterworth; Richard J Hayes
Journal:  AIDS       Date:  2007-02-19       Impact factor: 4.177

10.  Modelling the impact of antiretroviral use in resource-poor settings.

Authors:  Rebecca F Baggaley; Geoff P Garnett; Neil M Ferguson
Journal:  PLoS Med       Date:  2006-03-14       Impact factor: 11.069

View more
  135 in total

1.  Operational research to improve HIV prevention in the United States.

Authors:  Jeffrey H Herbst; Marlene Glassman; James W Carey; Thomas M Painter; Deborah J Gelaude; Amy M Fasula; Jerris L Raiford; Arin E Freeman; Camilla Harshbarger; Abigail H Viall; David W Purcell
Journal:  J Acquir Immune Defic Syndr       Date:  2012-04-15       Impact factor: 3.731

2.  Operationalizing treatment as prevention in Los Angeles County: antiretroviral therapy use and factors associated with unsuppressed viral load in the Ryan White system of care.

Authors:  Jennifer N Sayles; Jacqueline Rurangirwa; Min Kim; Janni Kinsler; Rangell Oruga; Mike Janson
Journal:  AIDS Patient Care STDS       Date:  2012-07-09       Impact factor: 5.078

3.  Antiretroviral therapy for tuberculosis control in nine African countries.

Authors:  Brian G Williams; Reuben Granich; Kevin M De Cock; Philippe Glaziou; Abhishek Sharma; Christopher Dye
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-25       Impact factor: 11.205

4.  HIV Treatment in Resource-Limited Environments: Treatment Coverage and Insights.

Authors:  Amin Khademi; Denis Saure; Andrew Schaefer; Kimberly Nucifora; R Scott Braithwaite; Mark S Roberts
Journal:  Value Health       Date:  2015-11-12       Impact factor: 5.725

5.  Should we try to eliminate HIV epidemics by using a 'Test and Treat' strategy?

Authors:  Bradley G Wagner; James S Kahn; Sally Blower
Journal:  AIDS       Date:  2010-03-13       Impact factor: 4.177

6.  Perfect counterfactuals for epidemic simulations.

Authors:  Joshua Kaminsky; Lindsay T Keegan; C Jessica E Metcalf; Justin Lessler
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2019-07-08       Impact factor: 6.237

7.  Barriers to Provider-Delivered Sexual Behavior Counseling for Youth Living with HIV/AIDS in the Democratic Republic of the Congo.

Authors:  L Parker; S Maman; A Pettifor; J L Chalachala; A Edmonds; C E Golin; K Moracco; F Behets
Journal:  J HIV AIDS Soc Serv       Date:  2013

Review 8.  Combination implementation for HIV prevention: moving from clinical trial evidence to population-level effects.

Authors:  Larry W Chang; David Serwadda; Thomas C Quinn; Maria J Wawer; Ronald H Gray; Steven J Reynolds
Journal:  Lancet Infect Dis       Date:  2013-01       Impact factor: 25.071

Review 9.  Antiretroviral-based HIV-1 prevention: antiretroviral treatment and pre-exposure prophylaxis.

Authors:  Connie Celum; Jared M Baeten
Journal:  Antivir Ther       Date:  2012-12-07

10.  Adaptation of a U.S. evidence-based Positive Prevention intervention for youth living with HIV/AIDS in Kinshasa, Democratic Republic of the Congo.

Authors:  L Parker; S Maman; A Pettifor; J L Chalachala; A Edmonds; C E Golin; K Moracco; F Behets
Journal:  Eval Program Plann       Date:  2012-09-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.